Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A method for screening drugs against pan-drug-resistant Acinetobacter baumannii using Caenorhabditis elegans

A technique for Acinetobacter baumannii and Caenorhabditis elegans, applied in the biological field

Active Publication Date: 2021-04-09
GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, the research on EPIs is mostly limited to in vitro experiments. Whether different EPIs can reverse the drug resistance of Acinetobacter baumannii in vivo to achieve a better antibacterial effect, and whether they will have a greater toxic effect is the current application of EPIs. Major issues that need to be resolved through in vivo experimental studies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A method for screening drugs against pan-drug-resistant Acinetobacter baumannii using Caenorhabditis elegans
  • A method for screening drugs against pan-drug-resistant Acinetobacter baumannii using Caenorhabditis elegans
  • A method for screening drugs against pan-drug-resistant Acinetobacter baumannii using Caenorhabditis elegans

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0041] Example 1 Establishment of Caenorhabditis elegans-pan-drug-resistant Acinetobacter baumannii infection model

[0042] 1. Test material

[0043] (1) Caenorhabditis elegans used in this example ( glp-4;sek-1 ), Escherichia coli ( E. coli ) OP50 was donated by Professor Chen Yanguang, School of Pharmacy, Sun Yat-sen University. The quality control strain Escherichia coli ATCC25922, and the clinically isolated pan-drug-resistant Acinetobacter baumannii (XDR-AB) were collected from ICU patients by the Laboratory Department of Guangzhou General Hospital of Guangzhou Military Command. Mérieux's VITEK-2 microbial automatic identification drug susceptibility instrument identification.

[0044] (2) CCCP (Carbonyl cyanide 3-chlorophenyl hydrazone), PAβN (phenyl-arginine-β-naphthylamide), polymyxin B (Polymyxin B sulfate salt), nalidixic acid, verapamil hydrochloride), reserpine (Reserpine), and omeprazole (Omeprazole) were purchased from Sigma Chemical Reagent Company of the ...

Embodiment 2

[0066] Example 2 Toxicity test of efflux pump inhibitors

[0067] 1. Wash the synchronously cultured nematodes to L4 stage with 20% BHI liquid medium into a 15mL centrifuge tube, wash three times at 500 r / min, 1min, and distribute 15-20 strips / well into a 96-well plate to 180μL, Add serial concentrations of efflux pump inhibitor CCCP, PAβN (5 μg / mL, 10 μg / mL, 15 μg / mL, 20 μg / mL, 25 μg / mL, 30 μg / mL, 35 μg / mL, 40 μg / mL), NMP, Austrian Meprazole, verapamil, reserpine (10 μg / mL, 20 μg / mL, 30 μg / mL, 40 μg / mL, 50 μg / mL, 60 μg / mL, 70 μg / mL, 80 μg / mL) 20 μL, at 25°C 1. Under the condition of 85% humidity for 30 hours without co-cultivation, the survival rate of nematodes was observed under a microscope, and the toxic effect of each efflux pump inhibitor on normal nematodes was judged.

[0068] 2. Results

[0069] The six efflux pump inhibitors CCCP, NMP, PAβN, omeprazole, verapamil and reserpine have different toxic effects on nematodes. Among them, when the concentration of CCCP is...

Embodiment 3

[0070] Example 3 In vitro drug susceptibility test of ciprofloxacin and various efflux pump inhibitors

[0071] 1. Microbroth dilution method to determine the minimum inhibitory concentration (MIC) of antibacterial drug ciprofloxacin

[0072] Escherichia coli ATCC25922 and Acinetobacter baumannii ATCC19606 were used as quality control strains for testing in the same batch. Prepare 5120 μg / mL antibacterial drug stock solution, take 13 sterile test tubes, and use CAMHB medium to prepare series concentrations of ciprofloxacin hydrochloride 512 μg / mL, 256 μg / mL, 128 μg / mL, 64 μg / mL , 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, 2 μg / mL, 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, take 100 μL each In a 96-well plate; use a photometric turbidimeter to take freshly cultured colonies and adjust the concentration of the bacterial suspension to 0.5 McFarland units (about 1.5×10 8 CFU / mL), 100 μL was added to each well to make the final concentration of bacteria 5×10 6 CFU / mL, the concent...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a method for screening drugs against pan-drug-resistant Acinetobacter baumannii by using Caenorhabditis elegans. First, a C. elegans-pan-drug-resistant Acinetobacter baumannii infection model for screening the efficacy of the composition was constructed, and the C. elegans had glp‑ 4;sek‑1 Double gene mutation; C. elegans-pandrug-resistant Acinetobacter baumannii co-culture medium consists of 20% BHI+5~20μM nalidixic acid+5~20μg / ml FeCl 3 ; The concentration of pan-resistant Acinetobacter baumannii is 1×10 6 ~1×10 9 CFU / mL; the duration of bacterial infection of C. elegans is 6-12 hours; the duration of drug treatment of infection model is 24-48 hours. The model can be used for rapid and high-throughput screening of the in vivo antibacterial activity of various compounds or drugs or compositions. Compared with the in vivo animal infection model, the model has the great advantages of low preparation cost, short cycle and simple operation. Compared with in vitro models, compounds with high toxicity in vivo, poor metabolism and low correlation between in vitro and in vivo can be screened out.

Description

technical field [0001] The invention belongs to the field of biotechnology. More specifically, it relates to a method for screening drugs against pan-drug-resistant Acinetobacter baumannii by using Caenorhabditis elegans. Background technique [0002] Acinetobacter baumannii ( Acinetobacter baumannii ) is a non-fermenting Gram-negative bacillus that widely exists in nature and hospital environments, and is one of the most common opportunistic pathogens causing nosocomial infections. Acinetobacter baumannii can cause a variety of infectious diseases including respiratory tract infection, urinary system infection, respiratory tract infection, bacteremia, wound infection, meningitis and ventilator-associated pneumonia, etc. The widespread use of the bacteria has produced great resistance to commonly used antibiotics, and even multi-drug resistance (resistance to 3 or more types of commonly used antibacterial drugs) Acinetobacter baumannii (MDR-AB) and extensively drug-resist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A01K67/02A61K49/00
CPCA01K67/02A61K49/0008
Inventor 姜志辉李健段欣冉何羡霞
Owner GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com